Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Weingart, Olaf ^a   Elter, Thomas ^a   Bauer, Kathrin ^a   Brillant, Corinne ^a   Herbst, Christine ^a   Monsef, Ina ^a   Skoetz, Nicole ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD20 ANTIBODY; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77950145831     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008079     Document Type: Review

References (33)

1. Binet 1981 Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al.A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198-206.
2. Bosch 2008 Bosch F, Abrisqueta P, Villamor N, Terol M, Ribera JM, Gonzalez-Barca E, et al.Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) Is a highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. ASH Conference Proceedings 2008:abstract 2097.
3. Byrd 2003 Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al.Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101(1):6-14.
4. Byrd 2005 Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al.Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105(1):49-53.
5. Chiorazzi 2005 Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. The New England Journal of Medicine 2005;352(8):804-15.
6. Coiffier 2008 Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, et al.Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111(3):1094-100.
7. Dohner 2000 Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al.Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine 2000;343(26):1910-6.
8. Eichhorst 2006 Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al.Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885-91.
9. Flinn 2007 Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al.Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology 2007;25(7):793-8.
10. Hallek 2008 Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al.Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56.
11. Hallek 2008a Hallek M, Fingerle-Rowson G, Fink A, Busch, R, Mayer J, Hensel M, et al.Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated uatients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH Conference Proceedings. 2008:abstract 325.
12. Higgins 2008 Higgins JPT, Deeks, JJ, Altman DG. Chapter 16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). Wiley-Blackwell, 2008:481-529.
13. Hillmen 2007 Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al.Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2007;25(35):5616-23.
14. Huhn 2001 Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al.Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98(5):1326-31.
15. Jacobs 2005 Jacobs SA, Foon KA. Monoclonal antibody therapy of leukaemias and lymphomas. Expert Opinion on Biological Therapy 2005;5(9):1225-43.
16. Keating 2005 Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al.Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4079-88.
17. Lau 2006 Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597-600.
18. Moreton 2005 Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al.Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 2005;23(13):2971-9.
19. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
20. Rai 1975 Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34.
21. Robak 2008 Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Current Opinion in Molecular Therapeutics 2008;10(3):294-309.
22. Robak 2008a Robak T, Moiseev SI, Dmoszynska A, Solal-Céligny P,Warzocha K, Loscertales J. Rituximab, fludarabine, and cyclophosphamide (RFC) prolongs progression free survival in relapsed or refractory Chronic lymphocytic leukemia (CLL) compared with FC alone: Final results from the International Randomized Phase III REACH Trial. ASH Conference Proceedings 2008:abstract LBA-1.
23. Robinson 2008 Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al.Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 2008;26(27): 4473-9.
24. Schmitz 2006 Schmitz S, Aly F, Steinmetz T, Diehl V, Rehwald U. Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma. Onkologie 2006;29(6):258-64.
25. Schulz 2002 Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, et al.Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100(9):3115-20.
26. Schünemann 2008 Schnemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings tables'. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). Wiley-Blackwell, 2008.
27. Sterne, 2008 Sterne, JAC, Egger M, Moher D. Adressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). Wiley-Blackwell, 2008:297-333.
28. Steurer 2006 Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2006, Issue 3.
29. Tam 2008 Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al.Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975-80.
30. Teeling 2004 Teeling JL, French RR, Cragg MS, van den BJ, Pluyter M, Huang H, et al.Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104(6):1793-800.
31. Tierney 2007 Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
32. Wierda 2005 Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al.Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 2005; 23(18):4070-8.
33. Wierda 2006 Wierda W, O'Brien S, Faderl S, Ferrajoli A,Wang X, Do KA, et al.A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006;106(2):337-45.